Co-amoxiclav

Co-amoxiclav

Co-amoxiclav is active against beta-lactamase-producing bacteria that are resistant to amoxicillin, and can be used to treat severe dental infection with spreading cellulitis or dental infection that has not responded to first-line antibacterial treatment.

Review patients who have received a course of antibiotic treatment.

If patients do not respond to first-line amoxicillin or metronidazole treatment, or in cases of severe infection with spreading cellulitis, an appropriate 5-day regimen is:

Co-amoxiclav 250/125 Tablets

Send: 15 tablets

Label: 1 tablet three times daily

Co-amoxiclav 25/125 Tablets

12 -17 years

As for adults

For adults:

Co-amoxiclav 250/125 Tablets

Send: 15 tablets

Label: 1 tablet three times daily

For children:

Co-amoxiclav 25/125 Tablets

12 -17 years

As for adults

NB:   Co-amoxiclav 250/125 tablets are amoxicillin 250 mg as trihydrate and clavulanic acid 125 mg as potassium salt.

Cholestatic jaundice can occur either during or shortly after the use of co-amoxiclav; this condition is more common in patients above the age of 65 years and in men. Do not prescribe co-amoxiclav to patients who have a history of co-amoxiclav-associated or penicillin-associated jaundice or hepatic dysfunction.

Co-amoxiclav, like other penicillins, can result in hypersensitivity reactions, including rashes and anaphylaxis, and can cause diarrhoea. Do not prescribe co-amoxiclav to patients with a history of anaphylaxis, urticaria or rash immediately after penicillin administration as these individuals are at risk of immediate hypersensitivity.

Drug interactions